Results 1 to 10 of about 36,269 (231)

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

New England Journal of Medicine, 2023
BACKGROUND Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle, C. Morizane, T. Karasic, T. Abrams, J. Furuse, R. Kelley, P. Cassier, H. Klümpen, H. Chang, Li-Tzong Chen, J. Tabernero, Do-Youn Oh, A. Mahipal, M. Moehler, E. Mitchell, Y. Komatsu, Kunihiro Masuda, Daniel H Ahn, R. Epstein, A. Halim, Yao Fu, T. Salimi, V. Wacheck, Yaohua He, Mei Liu, K. Benhadji, J. Bridgewater   +29 more
semanticscholar   +4 more sources

FGFR2 Inhibition in Cholangiocarcinoma.

Annual Review of Medicine, 2022
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical origin into intrahepatic (iCCA), perihilar, or distal
A. Vogel, O. Segatto, A. Stenzinger, A. Saborowski   +3 more
semanticscholar   +3 more sources

FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort

PLoS ONE, 2022
The significance of fibroblast growth factor receptor 2 (FGFR2) in gastric cancer (GC) has been studied predominantly in Asian patient cohorts. Data on White patients are scarce.
Thorben Schrumpf, Hans-Michael Behrens, Jochen Haag, Sandra Krüger, Christoph Röcken   +4 more
doaj   +3 more sources

Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Scientific Reports
FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (
Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Masaru Katoh, Simona Tavolari   +15 more
doaj   +2 more sources

Genomic complexity in advanced gastric and esophageal adenocarcinomas: a case report of rare WDR11-AS1-FGFR2 fusions [PDF]

Frontiers in Oncology
Fibroblast growth factor receptor 2 (FGFR2) alterations represent an emerging therapeutic target in gastroesophageal adenocarcinoma (GEA). Although FGFR2 amplifications and overexpression have been associated with poor prognosis and therapeutic ...
Eric Mehlhaff, Dustin A. Deming, Dustin A. Deming, Jeremy D. Kratz, Jeremy D. Kratz, Jeremy D. Kratz, Khaldun Obeidat, Lauren Welch, Nataliya Uboha, Nataliya Uboha   +9 more
doaj   +2 more sources

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Journal of Oncology, 2022
Aberrations in the fibroblast growth factor receptor2 (FGFR2) gene, including genetic alterations and chromosomal rearrangements, lead to the development and progression of cancer with poor prognosis.
S. Hyung, B. Han, Jaeyun Jung, S. Kim, J. Hong, S. Park, D. Zang, Joon-Oh Park, Y. Park, Kyoung-Mee Kim, W. Kang, Jeeyun Lee   +11 more
semanticscholar   +3 more sources

The Role of FGFR2 as a Novel Biomarker for Treatment of Gastric Cancer—A Literature Review [PDF]

Medicina
Background: Gastric cancer currently has the third highest mortality rate worldwide among cancer types. Despite gradual declines in mortality rates attributed to improvements in early detection and treatment, outcomes for advanced-stage disease are still
João Lages dos Santos, Rui Caetano Oliveira, João Martins Gama   +2 more
doaj   +2 more sources

Lower FGFR2 mRNA Expression and Higher Levels of FGFR2 IIIc in HER2-Positive Breast Cancer

Biology
Fibroblast growth factor receptor 2 (FGFR2) has been associated with breast cancer. We performed in silico analyses to investigate the FGFR2 mRNA expression and splice variants associated with breast cancer subtypes.
Thérèse Dix-Peek, Caroline Dickens, Juan Valcárcel, Raquel A. B. Duarte   +3 more
doaj   +3 more sources

Generation of human induced pluripotent stem cell lines from patients with FGFR2-linked syndromic craniosynostosis [PDF]

Disease Models & Mechanisms
Max Gijsbertsen, Irene M. J. Mathijssen, Ana F. Duarte Madancos, Johannes P. T. M. van Leeuwen, Jeroen van de Peppel   +4 more
doaj   +2 more sources

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Cancer Discovery, 2023
Unlike pan-FGFR inhibitors, RLY-4008 was designed to be selective for FGFR2 and induces clinical responses in FGFR2-altered solid tumors without clinically significant FGFR1-mediated hyperphosphatemia and FGFR4-mediated diarrhea.
V. Subbiah, V. Sahai, Dejan Maglic, Kamil Bruderek, B. Touré, Songping Zhao, R. Valverde, Patrick J O'Hearn, D. Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, B. M. Hudson, Damian Houde, Debjani Pal, Lindsey Foster, H. Gunaydin, P. Ayaz, Dina A Sharon, L. Goyal, A. Schram, Suneel D. Kamath, C. Sherwin, O. Schmidt-Kittler, K. Jen, F. Ricard, B. Wolf, D. Shaw, D. Bergstrom, J. Watters, Jessica B Casaletto   +30 more
semanticscholar   +1 more source